Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 12,400 shares, a drop of 17.3% from the February 13th total of 15,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.9% of the company’s shares are sold short.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Arcadia Biosciences in a report on Saturday. They set a “sell” rating for the company.
Get Our Latest Report on Arcadia Biosciences
Institutional Investors Weigh In On Arcadia Biosciences
Arcadia Biosciences Stock Performance
NASDAQ:RKDA traded up $0.16 on Wednesday, reaching $3.46. The company’s stock had a trading volume of 684 shares, compared to its average volume of 313,036. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $10.31. The business’s 50-day moving average price is $4.42 and its two-hundred day moving average price is $4.11. The firm has a market cap of $4.72 million, a PE ratio of -0.81 and a beta of 0.86.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Read More
- Five stocks we like better than Arcadia Biosciences
- How to Profit From Growth Investing
- D-Wave and Quantum Supremacy: Implications For Investors
- Conference Calls and Individual Investors
- 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
- What is a support level?
- Retail Sales Data Signals a Surge: The E-Commerce Stock Picks
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.